Tags : PF708

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies

Shots: Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories PF708 is a biosimilar referencing Eli Lilly’s […]Read More

Pfenex Reports Results of Human Factors Study for its PF708

The follow on study involves assessing of PF708 vs Forteo in 102 patients including 52 with osteoporosis and 50 with caregivers The study demonstrated PF708 had fewer or equal user errors showing 33% and 17 % of critical tasks respectively further concluded that the study data of user interface of the FDA-approved PF708 product is […]Read More

Pfenex and Alvogen Report EMA’s Acceptance of MAA for PF708

Shots: Pfenex and Alvogen announce that EMA has accepted MAA for its PF708, a biosimilar to Eli Lilly’s Forsteo which has generated $289M in EU & $1.6B globally in 2018 for the treatment of osteoporosis is expected to receive marketing authorization in all 28 states of EU, as well as in Iceland, Liechtenstein and Norway, […]Read More